Status:
RECRUITING
The Progress of Diabetes After Supaglutide Treatment in Type 2 Diabetes Patients
Lead Sponsor:
Nanjing First Hospital, Nanjing Medical University
Conditions:
Type 2 Diabetes Mellitus
Eligibility:
All Genders
18-75 years
Brief Summary
Glucagon like peptide-1 receptor agonist (GLP-1RA) can enhance insulin secretion and inhibit glucagon secretion in a glucose concentration dependent manner, delay gastric emptying, and reduce food int...
Detailed Description
With the rapid development of economy, the occurrence of diabetes in China has also shown a momentum of rapid growth. Dietary control and exercise are usually the foundation for treating T2DM. For pat...
Eligibility Criteria
Inclusion
- Complete a multicenter, randomized, double-blind, placebo-controlled clinical study on the efficacy of Supaglutide in T2DM patients with poor glucose control after dietary and exercise interventions (YN011-301);
- HbA1c ≤ 7.0%;
- The researchers determined that the patient's glucose control was stable based on the visit data of the subjects during the treatment with Supaglutide and the testing indicators of our hospital;
- The subjects agree to maintain scientific dietary and exercise habits throughout the entire research process, regularly conduct SMBG and keep records;
- Able to understand and willing to sign a written informed consent form and comply with the research protocol.
Exclusion
- The researchers believe that the subjects have a disease state where they cannot complete the observation period follow-up;
- The researchers determined that there were situations in the subjects that affected the compliance of this study during the treatment with Supaglutide.
Key Trial Info
Start Date :
March 13 2023
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
December 31 2025
Estimated Enrollment :
100 Patients enrolled
Trial Details
Trial ID
NCT06605287
Start Date
March 13 2023
End Date
December 31 2025
Last Update
September 20 2024
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Nanjing First Hospital, Nanjing Medical Univesity
Nanjing, China